Anti-inflammatory and Statin Combo May Stop Prostate Cancer
Administration of the popular anti-inflammatory drug Celebrex (celecoxib, a nonsteroidal anti-inflammatory drug) in combination with Lipitor (atorvastatin, a cholesterol lowering drug or statin) halts the transition of early prostate cancer to its more aggressive and potentially deadly stage.
“Anti-androgen therapy slows the prostate cancer but eventually the cancer becomes androgen-independent, the therapy becomes ineffective and the cancer cells become more aggressive,” said Xi Zheng, assistant research professor at Rutgers, The State University of New Jersey, who conducted the study.
“Treatments available for the later stage cancers are not very good,” said Allan Conney, director of Rutgers’ Susan Lehman Cullman Laboratory for Cancer Research, another researcher on the project. “Oncologists employ classical chemotherapy drugs which are very toxic and don’t work all that well.”
Such excitingly good news were the findings of researchers at the Rutgers’ Ernest Mario School of Pharmacy.
A combination of low doses of Lipitor and Celebrex had a more potent inhibiting effect on the formation of later stage tumors than a higher dose of either agent alone,” Zheng reported.
“The results from our study indicate that a combination of Lipitor and Celebrex may be an effective strategy for the prevention of prostate cancer progression from the first to the second stage.”
Clinical trial are being planned in the hope that same results will be generated.
Read more from Rutgers University.
Tags: androgen hormone, anti-inflammatory drugs, Celebrex, cholesterol-lowering-drugs, Lipitor, prostate-cancer, statinRelated Stories
POSTED IN: on anti-cancer ingredients, on prostate cancer
1 opinion for Anti-inflammatory and Statin Combo May Stop Prostate Cancer
Peter Belisi
Apr 17, 2008 at 11:49 pm
Good to know.
Have an opinion? Leave a comment: